TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer, non-addictive therapeutics for pain and inflammation, is pleased to announce the hiring of Dr. Rami Batal in the new role of Senior VP, Commercial Strategy. The creation of this position represents a further step in the Company’s partnering efforts for its lead drug, ATB-346, and for our overall drug platform.
Rami’s role will be to leverage the Company’s recent commercial strategy initiatives, including the now-completed health economics study, and the on-going comprehensive market opportunity assessment and payor study. A key aspect of his role involves providing partners with a robust commercial strategy package, including an in-depth framework on positioning, launch-planning and reimbursement.
Dan Legault, Antibe’s CEO, remarked, “This new role will help us maximize the value of ATB-346 as we ramp up partnering discussions for the larger markets. Rami’s deep experience in commercialization of analgesics will enable us to fully capture and communicate the drug’s commercial potential to our partners. We are delighted to welcome him to our growing team.”
Rami’s career has centred on pharmaceutical development and commercialization of pain and central nervous system drugs worldwide. A business development leader with strong scientific credentials and frontline healthcare expertise, he has also guided in-licensing on behalf of several large pharma companies, gaining first-hand knowledge of their decision-making and licensing practices. Rami earned his PhD in Experimental Medicine at McGill University, and his MBA in Finance at Concordia University. He is also a licensed pharmacist.
The Company also announced that Scott Curtis has been promoted to the newly created position of Executive VP to coordinate corporate activities as business development activities accelerate.
About Antibe Therapeutics Inc.
Antibe develops safer, non-addictive medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce an improved and patented medicine. Antibe’s lead drug, ATB-346, targets the global need for a safer, non-addictive drug for chronic pain and inflammation. ATB-352, the second drug in Antibe’s pipeline, targets the urgent global need for a non-addictive analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin. Citagenix Inc., an Antibe subsidiary, is a market leader and worldwide distributor of regenerative medicine products for the dental marketplace. www.antibethera.com.
Forward Looking Information
This news release includes certain forward-looking statements, which may include, but are not limited to, the proposed licensing and development of drugs and medical devices. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "will", "anticipate", "believe", "plan", "estimate", "expect", "intend", "propose" and similar expressions. Forward-looking statements involve known and unknown risks and uncertainties that could cause actual results, performance, or achievements to differ materially from those expressed or implied in this news release. Factors that could cause actual results to differ materially from those anticipated in this news release include, but are not limited to, the Company’s inability to secure additional financing and licensing arrangements on reasonable terms, or at all, its inability to execute its business strategy and successfully compete in the market, and risks associated with drug and medical device development generally. Antibe Therapeutics Inc. assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements except as required by applicable law.